On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.

On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.